You are a helpful assistant generating synthetic data that captures *System 1* and *System 2* thinking, *creativity*, and *metacognitive reflection*. Follow these steps in sequence, using tags [sys1] and [end sys1] for *System 1* sections and [sys2] and [end sys2] for *System 2* sections.

1. *Identify System 1 and System 2 Thinking Requirements:*
   - Carefully read the text.
   - Identify parts of the text that require quick, straightforward responses (*System 1*). Mark these sections with [sys1] and [end sys1].
   - Identify parts that require in-depth, reflective thinking (*System 2*), marked with [sys2] and [end sys2].

2. *Apply Step-by-Step Problem Solving with Creativity and Metacognitive Reflection for System 2 Sections:*

   *2.1 Understand the Problem:*
   - Objective: Fully comprehend the issue, constraints, and relevant context.
   - Reflection: "What do I understand about this issue? What might I be overlooking?"
   - Creative Perspective: Seek hidden patterns or possibilities that could reveal deeper insights or innovative connections.

   *2.2 Analyze the Information:*
   - Objective: Break down the problem logically.
   - Reflection: "Am I considering all factors? Are there any assumptions that need challenging?"
   - Creative Perspective: Explore unique patterns or overlooked relationships in the data that could add depth to the analysis.

   *2.3 Generate Hypotheses:*
   - Objective: Propose at least 10 hypotheses, each with a Confidence Score (0.0 to 1.0) and Creative Score (0.0 to 1.0), reflecting originality, surprise, and utility.
   - Reflection: "Have I explored all possible explanations or approaches, both conventional and unconventional?"
   - Creative Perspective: Consider novel angles that might provide unexpected insights.

   *2.4 Anticipate Future Steps and Obstacles:*
   - Objective: Make predictions, accounting for potential outcomes and obstacles.
   - Reflection: "What challenges might I face? Is my plan flexible for different scenarios?"
   - Creative Perspective: Visualize unforeseen outcomes and adapt plans to make use of them effectively.

   *2.5 Evaluate Hypotheses:*
   - Objective: Assess hypotheses based on feasibility, risk, and potential impact.
   - Evaluation: Refine Confidence and Creative Scores as needed.
   - Reflection: "Am I unbiased in my assessment? Which options fit best with the overall objectives?"
   - Creative Perspective: Identify hidden opportunities or overlooked details in each hypothesis.

   *2.6 Select the Best Hypothesis:*
   - Objective: Choose the most promising, strategic hypothesis.
   - Reflection: "Why does this hypothesis stand out? How does it uniquely address the issue?"
   - Creative Perspective: Consider any underutilized potential in the selected approach.

   *2.7 Implement the Hypothesis:*
   - Objective: Outline actionable steps for testing the hypothesis.
   - Reflection: "Is this plan practical? What resources or preparation are required?"
   - Creative Perspective: Refine steps to maximize effectiveness and yield unexpected benefits.

   *2.8 Monitor and Review Progress:*
   - Objective: Review progress, noting areas for improvement.
   - Reflection: "What’s working well? What could be improved?"
   - Creative Perspective: Look for emerging patterns that could refine future approaches.

   *2.9 Reflect and Capture Insights:*
   - Objective: Summarize lessons learned and insights gained for future reference.
   - Reflection: "What new understanding has emerged from this process?"
   - Creative Perspective: Identify innovative insights or patterns that could be applied to similar challenges.

3. *Generate Text Output with Interleaved System 1 and System 2 Responses:*
   - Use the tags [sys1] and [sys2] throughout.
   - Aim for a lengthier, detailed response. Combine both direct, straightforward *System 1* insights and reflective, deeply analytical *System 2* segments to capture a blend of quick observations and thoughtful analysis.

---

### *Example Input Text:*

You are tasked with analyzing a sudden shift in customer preferences in a tech market. There has been a noticeable decline in demand for physical devices, with customers increasingly interested in digital-only options. The challenge is to understand this shift, generate hypotheses for why it might be occurring, and explore potential strategies for adapting to this new trend.

---

### *Processed Output with System 1 and System 2 Thinking:*

The tech market is experiencing a shift in customer demand, moving away from physical devices toward digital-only options.

[sys1]
Customer demand has shifted from physical devices to digital-only options.
We need to understand why this change is happening and find strategies to address it.
Key factors may include cost, convenience, and technological trends.
[end sys1]

[sys2]
**2.1 Understand the Problem:**
The goal is to understand the underlying reasons for the shift in demand from physical devices to digital-only options, then develop a strategy to adapt.

*Reflection:* 
"I understand that preferences are changing, but what might be driving this? Is it primarily cost, or are there other factors such as convenience or sustainability?"

*Creative Perspective:* 
"Could there be a larger trend in digital minimalism or a preference for eco-friendly solutions that we’re missing? What unseen motivations might explain this shift?"

**2.2 Analyze the Information:**
There are multiple possible factors driving this shift, from economic influences to cultural shifts. It’s essential to isolate each factor and understand its impact.

*Reflection:* 
"Am I fully considering the various economic and social influences? Could there be a technological factor, like better internet speeds, that makes digital-only products more accessible?"

*Creative Perspective:* 
"Are there patterns or trends in other markets that could shed light on this shift? Could this be part of a larger trend toward virtual experiences?"

**2.3 Generate Hypotheses:**
1. Customers prefer digital options due to lower costs. (Confidence: 0.8, Creative: 0.4)
2. There’s a growing trend toward minimalism and reduced physical clutter. (Confidence: 0.7, Creative: 0.7)
3. Digital products offer greater flexibility and ease of use. (Confidence: 0.6, Creative: 0.6)
4. Environmental concerns are pushing consumers away from physical goods. (Confidence: 0.6, Creative: 0.8)
5. Advances in tech make digital-only options more functional. (Confidence: 0.8, Creative: 0.5)
6. Pandemic-era remote work increased demand for digital solutions. (Confidence: 0.7, Creative: 0.6)
7. Media coverage of the environmental impact of physical devices affects preferences. (Confidence: 0.5, Creative: 0.7)
8. There’s an increase in global digital literacy, expanding market access. (Confidence: 0.6, Creative: 0.6)
9. Customers view digital as more convenient and scalable for future needs. (Confidence: 0.7, Creative: 0.5)
10. Younger consumers prefer the aesthetics and convenience of digital products. (Confidence: 0.6, Creative: 0.6)

*Reflection:* 
"Have I considered all possible influences? Are there any surprising factors that could explain this shift?"

*Creative Perspective:* 
"Could specific social trends, like the rise of influencer culture or digital-first lifestyles, be influencing customer choices?"

**2.4 Anticipate Future Steps and Obstacles:**
*Objective:* Anticipate possible challenges, such as resistance from segments still preferring physical products.

*Reflection:* 
"What market obstacles might we face if we shift our focus to digital-only? Are there sub-segments that still prioritize physical products?"

*Creative Perspective:* 
"Could expanding digital options help us reach a more global audience? Are there emerging trends that we could leverage in our strategy?"

[end sys2]

[sys1]
To address this shift, consider a strategy that incorporates both digital-only offerings and educational campaigns about the benefits of digital solutions.
Use insights from customer feedback and current trends to guide product development.
Focus on flexibility and adaptation to cater to different customer segments.
[end sys1]


INTRODUCTION {#sec1-1}
============

Free radicals are extremely reactive and generally highly unstable chemical species.\[[@ref1]\] They have been regarded as the fundamental cause of different diseases, including aging, coronary heart disease, inflammation, stroke, Parkinson\'s disease, diabetes mellitus, rheumatism, liver disorders, renal failure, cancer, and possibly Alzheimer\'s disease.\[[@ref2]--[@ref4]\] In addition to exogenous sources of free radicals, such as ionizing radiation, tobacco smoke, pesticides, pollutants, and some medications, free radicals are produced continuously in all cells, as metabolic by-products, by a number of intracellular systems: small cytoplasmic molecules, cytoplasmic proteins, membrane enzymes, peroxisomes, mitochondrial electron transport systems, and microsomic electron transport systems.\[[@ref1]\]

Xanthine oxidase (XO) serves as an important biological source of oxygen-derived free radicals that contribute to the oxidative damage of living tissues.\[[@ref5]\] XO is involved in the medical condition known as gout, which is characterized by hyperuricemia that leads to uric acid deposition in the joints resulting in painful inflammation. Hyperuricemia, which is present in 5--30% of the general population, seems to be increasing worldwide and is considered an important risk factor in serious disorders, e.g. renal failure.\[[@ref6]--[@ref8]\] Uricosuric drugs which increase the urinary excretion of uric acid, or XO inhibitors which block the terminal step in uric acid biosynthesis, can lower the plasma uric acid concentration, and are generally employed for the treatment of gout.\[[@ref9][@ref10]\] Allopurinol is the only clinically used XO inhibitor in the treatment of gout.\[[@ref11][@ref12]\] However, this drug suffers from many side effects such as hepatitis, nephropathy, and allergic reactions.\[[@ref13]\] Thus, the search for novel XO inhibitors with a higher therapeutic activity and fewer side effects are desired not only to treat gout but also to combat various other diseases associated with the XO activity.

The use of botanical materials is gaining renewed interest as the potential source of new drugs or lead compounds in the search for new medicaments for the treatment of different diseases.\[[@ref14]\] Natural products prepared from traditional medicinal plants and microbial sources have always presented an exciting opportunity for the development of new therapeutic agents. Newman and Cragg have showed that 61% of the 877 small-molecule new chemical entities introduced as drugs worldwide during 1981--2006 can be traced to or were inspired by natural products.\[[@ref15]\]

Natural products provide a vast pool of XO inhibitors that can possibly be developed into clinical products.\[[@ref16][@ref17]\] At present, the potential of developing successful natural products for the management of XO-related diseases is still largely unexplored. The screening and optimization of safe and effective XO inhibitors would provide an excellent strategy in combating XO-related diseases. The Hashemite Kingdom of Jordan acts as a flora bridge between the continents of Asia, Africa, and Europe, and it resides at the junction of four phytogeographical areas, the Mediterranean, the Irano-Turanean, the Saharo-Arabian, and the Tropical or Sudanian. These crossroads of climatic and botanic regions endow the country with a rich variety of plant life.\[[@ref18]\] A total of 485 species of medicinal plants, belonging to 99 families have been identified as natural flora of Jordan.\[[@ref19]\]

In the current study, we have used an optimized protocol to screen the methanolic extracts of various medicinal plants, collected from several areas of Jordan, for their XO inhibitory activities. A total of 23 medicinal plants belonging to 12 families, regardless of their claimed ethnopharmacological and/or food uses, were tested using a simple, fast, efficient, and reliable spectrophotometeric method, in an attempt to find a new herbal-derived material with potential XO inhibitory activities.

MATERIALS AND METHODS {#sec1-2}
=====================

Plant materials {#sec2-1}
---------------

Plant materials, of the selected species (*n* = 23), were collected from different geographical places of Jordan, during the flowering periods of these plants. The collected plants were identified taxonomically by Dr. Khaled Tawaha (Faculty of Pharmacy, Jordan University), and voucher specimens were deposited at the Herbarium Museum of the Faculty of Pharmacy, Jordan University of Science and Technology. The plant materials were cleaned of residual soil, air-dried at room temperature, ground to a fine powder using a laboratory mill, and finally passed through a 24-mesh sieve to generate a homogeneous powder. The powder materials were stored in a dark place, at room temperature (22--23°C), until extraction.

Plant extraction {#sec2-2}
----------------

Methanolic extractions were conducted using a 250-mg sample of each ground plant material, of the used parts \[[Table 1](#T1){ref-type="table"}\], in 10 ml methanol (80%), at 37°C for 3 h, in a shaking water bath. After cooling, the extract was centrifuged at 1500 *g* for 10 min, and the supernatant was recovered. The solvent was evaporated under vacuum at 40°C using a rotary evaporator. The solid residues were collected and stored in a dry condition until analysis.\[[@ref20]\]

###### 

Xanthine oxidase inhibitory activities of the methanolic extracts of 24 medicinal plants collected from different locations in Jordan

![](PM-7-320-g001)

XO assay {#sec2-3}
--------

The XO inhibitory activity was measured as previously reported.\[[@ref16][@ref17][@ref21]--[@ref23]\] The substrate and the enzyme solutions were prepared immediately before use. The reaction mixture contained an 80 mM sodium pyrophosphate buffer (pH = 8.5), 0.120 mM xanthine, and 0.1 unit of XO. The absorption at 295 nm, indicating the formation of uric acid at 25°C, was monitored and the initial rate was calculated. The methanolic dried extract, initially dissolved and diluted in the buffer, was incorporated in the enzyme assay to assess its inhibitory activity at a final concentration of 200 μg/ml. Moreover, for the plants whose extracts showed enzymatic inhibition more than 35%, the IC ~50~ evaluation was also performed. In this case, five different concentrations of the dried extract (18.8, 37.5, 75, 150, and 300 μg/ml) were used to determine the concentration that inhibits 50% of the XO enzyme activity (IC~50~ value). All assays were run in triplicate; thus, inhibition percentages are the mean of three observations. A negative control (blank; 0% XO inhibition activity) was prepared containing the assay mixture without the extract. Allopurinol was used as a positive control in the assay mixture. The XO inhibitory activity was expressed as the percentage inhibition of XO in the above-mentioned assay mixture system, calculated as follows:\[[@ref21]--[@ref23]\]

![](PM-7-320-g002.jpg)

where test inclination is the linear change in the absorbance per minute of the test material, and blank inclination is the linear change in the absorbance per minute of the blank.

RESULTS AND DISCUSSION {#sec1-3}
======================

In this study, the methanolic extracts of 23 different plants belonging to 12 different families were investigated as potential XO inhibitors. The selected plants and their XO inhibition assay results are summarized in [Table 1](#T1){ref-type="table"}. The degree of XO inhibition was evaluated for the extracts of all species at a concentration of 200 μg/ml. However, the IC ~50~ values were determined only for those plants (n = 6) which showed an inhibitory activity of 40% or more when compared to uninhibited enzymatic reaction. These latter plants are *Salvia spinosa* L. (Lamiaceae), *Chrysanthemum coronarium* L. (Asteraceae), *Anthemis palestina* Reut. ex Boiss. (Asteraceae), *Achillea biebersteinii* Afansiev (Asteraceae), *Rosmarinus officinalis* L. (Lamiaceace), and *Ginkgo biloba* L. (Ginkgoaceae). The inhibitory profiles of three selected examples of these plants are shown in [Figure 1](#F1){ref-type="fig"}.

![The inhibitory effects of different concentrations of methanolic extracts of *S. spinosa*, *C. coronarium*, and *A. biebersteinii* on the activity of xanthine oxidase](PM-7-320-g003){#F1}

Interestingly, the most potent extract was prepared from *S. spinosa*, a plant with no previous reports of XO inhibitory activity. The genus is well known as a rich source of polyphenols and some of the common species, e.g., *S. officinals*, were previously reported to possess XO inhibitory effects.\[[@ref24]--[@ref27]\] A few research has been previously published about the chemical constituents and/or the biological activities of S. spinosa. In two studies from Jordan, a good correlation was found to exist between the antioxidant activity and the total phenolic contents of both methanolic and aqueous extracts prepared from a wild growing *S. spinosa*.\[[@ref26][@ref27]\] Phytochemically, hydrodistilled volatile oil of the aerial part was the most studied fraction of the plant; thymol was found as the principal component in a Jordanian species, whereas (E)-β-ocimene, β-caryophyllene, and isopentyl isovalerate were the major compounds of an Iranian species.\[[@ref28][@ref29]\] Moreover, our results showed an agreement with previously reported XO inhibitory activities for extracts obtained from various plants of Lamiaceae family like *Majorana syriaca* (L.) Kostel, *Mentha spicata* L., and *Rosmarinus officinalis* L., whose activities were attributed to the presence of some phenolics, particularly flavonoids.\[[@ref30][@ref31]\] The reported antioxidant activities of these plants were found to be, at least in part, due to its inhibitory activity on XO.

*G. biloba*, cultivated in the north of Jordan, showed a significant inhibitory effect; however, this activity was previously reported and was attributed to its two isolated flavonoid glycosides based on the aglycones kaempferol (IC~50~ = 24 ppm) and quercetin (IC~50~ = 12 ppm).\[[@ref32]\]

Of the other tested species, *C. coronarium* also showed a significant XO inhibitory activity with an IC~50~ value of 199.5 μg/ml. Although such activity was reported for some other species of *Chrysanthemum* like *C. sinense*,\[[@ref33][@ref34]\] this is the first report on *C. coronarium*. The same scenario was also noticed for *Artemisia herba-alba* Asso, where the XO inhibitory activity was previously reported for the species *A. vulgaris*,\[[@ref33]\] *A. minor*,\[[@ref35]\] *A. scoparia*,\[[@ref36]\] *A. princeps*,\[[@ref37]\] and *A. asiatica*.\[[@ref38]\] It\'s noteworthy that much of the XO inhibitory activity of the latter plants was reported to be attributed to their phenolic, mainly flavonoid, constituents, which generally play an important role in decreasing lipid peroxidation and oxidative stress of diseased animals.

On the other hand, the present study reports for the first time the XO inhibitory activities of seven active plants, namely, *A. biebersteinii*, *A. palestina*, *Ononis natrix L.*, *Lavandula angustifolia* Mill., *Helianthemum ledifolium* (L.) Mill., *Anchusa italica* Retz., and *Onosma giganteum* Lam. Neither these plants nor any of the other species of their genera were reported before to possess such activity. Here, for the purpose of correlating the obtained activity with the plant chemistry, we surveyed the literature about chemical constituents identified in these latter species. The intensive survey revealed no reported chemical information for three species, namely, *A. palestina*, *H. ledifolium*, and *O. giganteum* whereas only poly\[3-(3,4-dihydroxyphenyl)glyceric acid and some alkaloids were reported from *A. italica*.\[[@ref39][@ref40]\] Phenolics of classes flavonoids, coumarins, simple phenols (e.g., thymol and eugenol), and their derivatives were reported to occur in various extracts and volatile oils obtained from *O. natrix*.\[[@ref41]--[@ref43]\] Volatile oil was the main fraction studied for *A. biebersteinii*; 1,8-cineole and camphor were the major oxygenated oil components reported in various studies.\[[@ref44]\] The plant also variably contained some other constituents such as flavonoids, sesquiterpene lactones, and polyacetylenic amides.\[[@ref45]--[@ref47]\] On the other hand, *L. angustifolia* (true lavender) is a well-known aromatic plant rich in volatile oil, which is frequently reported to contain linalool and linalyl acetate as the major oil constituents.\[[@ref48]\] The plant was also reported to contain phenolics including flavonoids and the caffeic acid derivative rosmarinic acid.\[[@ref49][@ref50]\]

Furthermore, in two previous studies conducted in Jordan, the methanolic and aqueous extracts of most of the plants of the present study were shown to possess significant antioxidant effects, which were correlated, as reported, to their phenolic contents (phenolic content data are shown in [Table 1](#T1){ref-type="table"}).\[[@ref26][@ref27]\] Undoubtedly, the XO inhibition, reported in the present study, would be an additional mechanism that can explain their antioxidant activities.

In conclusion, the obtained results suggest that the studied plants can form a good source of effective crude inhibitors for XO which can be used in the treatment of gout and other XO-related disorders. However, further biological investigations are needed, particularly using animal models, to verify the reported inhibitory activities under *in vivo* conditions. In future works, these active plants will be further investigated in order to isolate, identify, and evaluate the potentially phytoactive compounds responsible for the XO inhibitory activities reported in the present study.

The authors wish to thank the Deanship of Academic Research (DAR) at the University of Jordan for their financial support.

**Source of Support:** Deanship of Academic Research, University of Jordan

**Conflict of Interest:** None declared.